olfactory receptor family 2 subfamily AT member 1 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR2AT1P profile across patient tissues and cancer cell-line models. OR2AT1P expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, OR2AT1P is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, OR2AT1P RNA expression shows 6,752 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, KIRC, and STAD as cancer lineages where OR2AT1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR2AT1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR2AT1P survival associations across molecular data types. OR2AT1P RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR2AT1P RNA expression–survival associations across cancer types. High OR2AT1P expression shows unfavorable associations in LIHC, UCEC, KIRC, PCPG and CHOL, but favorable associations in PAAD. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for OR2AT1P RNA expression.
This table summarizes OR2AT1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR2AT1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR2AT1P shows lower tumor expression in LUAD, LUSC, BRCA and THCA and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher OR2AT1P RNA expression in tumor versus normal tissue (log2 FC = +0.528, t-test p < 0.001).
This table shows molecular features associated with OR2AT1P in patient tissues and cancer cell lines. In patient samples, OR2AT1P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
